Caplacizumab-yhdp

Category: Blood Clotting (Hemostasis)

Caplacizumab-yhdp Overview

Caplacizumab (INN; trade name Cablivi) is a bivalent Single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2] This drug was developed by Ablynx NV.[3] On 31 August 2018 it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".[4&...

Read more Caplacizumab-yhdp Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Caplacizumab

Recent Caplacizumab-yhdp Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Caplacizumab-yhdp or a similar ingredient: (1 result)

• CABLIVI Caplacizumab-yhdp